Immunoscape Ltd. closed an $11 million global equity financing round led by U.S.-based venture firm Anzu Partners along with University of Tokyo Edge Capital in Japan, and Indonesia's NPR Holdings. The company plans to use the funds to ramp up its immune profiling technology platform, which performs deep T-cell analysis, and expand partnerships to develop vaccines for COVID-19 and other viruses as well as targeted oncology therapies.

In the Dec. 20, 2019, issue of Science, Stefan Kaufmann, who is the founding director of the Max Planck Institute for Infection Biology, and his colleagues report that the immune system could calibrate its response to Pseudomonas aeruginosa by monitoring the bacterial quorum sensing chatter.